MedPath

Safety and efficacy of intra-articular injection of platelet rich plasma in patients with ankle osteoarthritis

Not Applicable
Conditions
Ankle osteoarthritis
Registration Number
JPRN-UMIN000028601
Lead Sponsor
Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University
Brief Summary

o serious adverse effects were observed related with intra-articular injection of platelet rich plasma. The VAS scores significantly decreased from baseline to 4, 12, and 24 weeks after treatment. The JSSF scale score and the pain and pain-related subscale score of the SAFE-Q significantly improved from baseline to 12 weeks after treatment.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
20
Inclusion Criteria

Not provided

Exclusion Criteria

1 Anemia (hemoglobin levels less than 11mg/dl) 2 Thrombocytopenia (platelet levels less than 150*103/ul) 3 History of ankle surgery or ankle fracture within the past 12 months 4 Treatment with steroid or hyaluronic acid injections within the past 6 months 5 Treatment with oral anticoagulant 6 Systemic inflammatory disease (eg rheumatoid arthritis) 7 Renal failure 8 Hepatic failure 9 Diabetes mellitus (HbA1c more than 9.0) 10 Psychological disease 11 Pregnancy 12 Infection of the ankle 13 Cancer or malignant lesions

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath